Insider Selling: Insmed Incorporated (NASDAQ:INSM) CFO Sells $112,898.50 in Stock

Insmed Incorporated (NASDAQ:INSM) CFO Sara Bonstein sold 1,579 shares of the stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $71.50, for a total value of $112,898.50. Following the sale, the chief financial officer now owns 113,288 shares in the company, valued at $8,100,092. The trade was a 1.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Sara Bonstein also recently made the following trade(s):

• On Wednesday, May 14th, Sara Bonstein sold 1,634 shares of Insmed stock. The stock was sold at an average price of $65.61, for a total transaction of $107,206.74.
• On Tuesday, May 13th, Sara Bonstein sold 8,870 shares of Insmed stock. The shares were sold at an average price of $67.81, for a total transaction of $601,474.70.

Insmed Stock Performance

Shares of Insmed stock opened at $73.62 on Friday. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The stock’s fifty day moving average price is $69.28 and its 200-day moving average price is $73.03. The firm has a market cap of $13.41 billion, a P/E ratio of -13.17 and a beta of 0.80. Insmed Incorporated has a 12 month low of $55.74 and a 12 month high of $84.91.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The business had revenue of $92.82 million for the quarter, compared to the consensus estimate of $91.63 million. During the same quarter in the previous year, the company earned ($1.06) earnings per share. The firm’s revenue was up 22.9% on a year-over-year basis. On average, equities research analysts expect that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

INSM has been the topic of several analyst reports. Bank of America upped their price target on shares of Insmed from $92.00 to $96.00 and gave the company a “buy” rating in a report on Thursday, March 20th. Wells Fargo & Company upped their target price on Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research note on Wednesday, February 19th. Jefferies Financial Group started coverage on Insmed in a report on Tuesday, May 13th. They issued a “buy” rating and a $105.00 price target on the stock. Stifel Nicolaus dropped their price objective on Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a report on Friday, February 21st. Finally, Truist Financial upped their price objective on Insmed from $105.00 to $108.00 and gave the company a “buy” rating in a research report on Friday, February 21st. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat, Insmed presently has an average rating of “Moderate Buy” and an average price target of $96.73.

Hedge Funds Weigh In On Insmed

Several institutional investors have recently bought and sold shares of INSM. Strs Ohio purchased a new stake in Insmed during the first quarter worth $1,961,000. Intech Investment Management LLC raised its position in shares of Insmed by 43.2% in the 1st quarter. Intech Investment Management LLC now owns 101,979 shares of the biopharmaceutical company’s stock worth $7,780,000 after acquiring an additional 30,752 shares in the last quarter. Bayforest Capital Ltd lifted its stake in shares of Insmed by 255.0% during the 1st quarter. Bayforest Capital Ltd now owns 7,054 shares of the biopharmaceutical company’s stock worth $538,000 after purchasing an additional 5,067 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Insmed by 10.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 539,484 shares of the biopharmaceutical company’s stock valued at $41,157,000 after purchasing an additional 52,637 shares in the last quarter. Finally, Woodline Partners LP grew its stake in Insmed by 53.3% in the first quarter. Woodline Partners LP now owns 248,770 shares of the biopharmaceutical company’s stock valued at $18,979,000 after purchasing an additional 86,540 shares during the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.